Insights
Search Results
Client Highlights
6.05.26
Firm Advises Ona Therapeutics on IP Matters Related to $86.6 Million Series B
On June 4, 2026, Ona Therapeutics, a global biopharmaceutical company pioneering first-in-class antibody-drug conjugates (ADCs) to address treatment-resistant cancers, announced the closing of an oversubscribed $86.6 million Series B financing. The round was co-led by new investors Columbus Venture Partners and Mérieux Equity Partners, with participation from additional investors COFIDES and Korys, alongside all existing investors Alta Life Sciences, Asabys Partners, Bpifrance, as part of the InnoBio investment strategy, CDTI through SICC Innvierte, FundPlus NV, and Ysios Capital. Wilson Sonsini Goodrich & Rosati advised Ona Therapeutics on IP matters related to the transaction.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
The proceeds from the Series B will be used to advance the clinical development of Ona’s lead program, ONA-255, a first-in-class ADC initially focused on breast cancer, and to progress ONA-389, a second first-in-class ADC targeting colorectal cancer. ONA-255 is designed to address treatment-resistant tumor biology through a differentiated mechanism aimed at improving the therapeutic index compared to earlier approaches. ONA-389 will advance toward first-in-human studies, expanding Ona’s pipeline in indications with significant unmet need. Ona currently retains full worldwide commercial rights to all its assets.
Client Highlights
3.31.26
Wilson Sonsini Advises Centessa on IP Matters Related to Acquisition by Lilly
On March 31, 2026, Centessa Pharmaceuticals, a clinical-stage company developing a new class of medicines for the treatment of excessive daytime sleepiness and other neurological conditions, announced a definitive agreement for Eli Lilly and Company (Lilly), an American multinational pharmaceutical company, to acquire Centessa. Under the terms of the transaction agreement, Lilly will acquire all of the issued and to be issued share capital of Centessa (including the American Depositary Shares (ADSs) representing ordinary shares) for $38.00 in cash per share plus one non-transferrable contingent value right (CVR) that entitles the holder to receive up to an aggregate of $9.00 subject to the achievement of three milestones described below, for total potential aggregate per share consideration of up to $47.00. The upfront cash consideration represents an aggregate equity value of approximately $6.3 billion and the CVR represents an additional potential aggregate equity value of approximately $1.5 billion. Wilson Sonsini Goodrich & Rosati advised Centessa in IP matters related to the transaction.
Client Highlights
3.12.26
Firm Advises Day One on IP Matters Related to $2.5 Billion Acquisition by Servier
On March 6, 2026, Servier, an independent international pharmaceutical group governed by a foundation, and Day One Biopharmaceuticals, a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced that they have entered into a definitive agreement for Servier to acquire Day One for $21.50 per share in cash, representing a total equity value of approximately $2.5 billion. Wilson Sonsini Goodrich & Rosati advised Day One on IP matters related to the transaction.
Client Highlights
11.19.25
Wilson Sonsini Advises Day One on IP Matters Related to Acquisition of Mersana
On November 13, 2025, Day One Biopharmaceuticals (Day One), a biopharmaceutical company dedicated to developing and commercializing targeted therapies for people of all ages with life-threatening diseases, announced it has signed a definitive merger agreement to acquire Mersana Therapeutics (Mersana). Wilson Sonsini Goodrich & Rosati advised Day One on IP due diligence related to the transaction.
Client Highlights
2.15.24
Wilson Sonsini Advises Metagenomi on IP Matters Related to $93 Million IPO
On February 13, 2024, Metagenomi, Inc., a precision genetic medicines company committed to developing curative therapeutics for patients using its proprietary, comprehensive metagenomics-derived gene editing toolbox, announced the closing of its previously announced initial public offering of 6,250,000 of its common stock at a price to the public of $15.00 per share. The shares began trading on the Nasdaq Global Select Market on February 9, 2024, under the ticker symbol “MGX.” The aggregate gross proceeds to Metagenomi from the offering were approximately $93.75 million, before deducting underwriting discounts and commissions and offering expenses. In addition, Metagenomi has granted the underwriters a 30-day option to purchase up to an additional 937,500 of its common stock at the initial public offering price less underwriting discounts and commissions.